Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | MicrobiomeTrials← Back to trialsNCT03816332
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2019-11-08Est. Completion: 2022-10-11
Enrollment target: 12 participants Locations- Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United StatesEst. completion Dec 31, 2026
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
Recurrent Melanoma
Unresectable Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trameti…
Birmingham, United StatesEst. completion Sep 30, 2023
Acral Lentiginous MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Mucosal Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high…
Birmingham, United StatesEst. completion Sep 1, 2022